Cover Image
市場調查報告書

亞太地區無侵入性出生前遺傳學的檢驗(NIPT)市場

Emerging NIPT Market in Asia Pacific

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 290009
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區無侵入性出生前遺傳學的檢驗(NIPT)市場 Emerging NIPT Market in Asia Pacific
出版日期: 2013年11月01日 內容資訊: 英文 50 Pages
簡介

無侵入性產前遺傳檢測(NIPT),在分子診斷市場中達成急速成長。在美國最初開始的檢驗,預計2012年∼2017年以CAGR49%成長。風險高的孕婦廣泛接受是最大的促進成長要素。這個檢驗的唐氏症檢測靈敏度達99%以上,完全去除侵入性產前檢查伴隨的風險。

本報告提供亞太地區NIPT市場相關調查分析、主要國家的市場預測,為您概述為以下內容。

第1章 分析師的見解

第2章 調查手法

第3章 簡介

第4章 亞太地區NIPT市場預測

  • 澳洲
    • 市場潛在性
    • 市場概要
    • 法規方案
  • 中國
    • 市場潛在性
    • 市場概要
    • 法規方案
  • 日本
    • 市場潛在性
    • 市場概要
    • 法規方案
  • 印度
    • 市場潛在性
    • 市場概要
    • 法規方案

圖表

目錄

Non-Invasive Prenatal Testing (NIPT) has catapulted the growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during 2012-2017. This growth can be attributed to several factors, foremost of all being its high acceptance amongst high-risk pregnant mothers. The tests have a more than 99% sensitivity of detecting Down's syndrome and completely eliminate the risk associated with invasive prenatal tests like CVS and Amniocentesis, gaining them instant popularity amongst the consumers.

But due to a restrictive potential population base in the US, which is estimated at around 700,000, players based in the region were quick to expand beyond their base and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For our study, we have selected the APAC region since it represents a highly underpenetrated market with immense potential for growth.

APAC houses almost a third of global population. According to our report, “Emerging NIPT Market in Asia Pacific” there are around 1 Million potential patients in the region representing a greater than US$ 1 Billion market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for players. China is another major region where two local players; BGI and Berry Genomics are expected to collectively accession around 100,000 tests in 2013 alone.

The report covers exhaustive analysis of the potential population for NIPT tests in each region. Different scenarios have been explored in line with the regulatory environment in a given region. Detailed description of current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them etc. has also been provided.

Besides, test volumes and markets till 2018 have been forecasted. The forecast is conducted on the basis of co-relation and judgmental analysis, which is carried out after carefully studying key factors including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario and various other drivers and challenges.

Overall, the report presents optimum information and transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction

  • 3.1. MaterniT21 PLUS
  • 3.2. Verifi
  • 3.3. Panorama
  • 3.4. Harmony
  • 3.5. NIFTY
  • 3.6. Bambni
  • 3.7. Association of Down's syndrome Risk to Fetus with Mother's Age

4. Asia-Pacific NIPT Market Outlook to 2018

  • 4.1. Australia
    • 4.1.1. Market Potential
    • 4.1.2. Market Overview
    • 4.1.3. Regulatory Scenario
  • 4.2. China
    • 4.2.1. Market Potential
    • 4.2.2. Market Overview
    • 4.2.3. Regulatory Scenario
  • 4.3. Japan
    • 4.3.1. Market Potential
    • 4.3.2. Market Overview
    • 4.3.3. Regulatory Scenario
  • 4.4. India
    • 4.4.1. Market Potential
    • 4.4.2. Regulatory Scenario

List of Figures:

  • Figure 4-1: Australia - Number of Births (‘000), 2013-2018
  • Figure 4-2: Australia - Number of Births by Mother's Risk of Down's syndrome (%), 2011
  • Figure 4-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
  • Figure 4-4: Australia - NIPT Market (Million US$), 2013-2018
  • Figure 4-5: Australia - NIPT Market (Volume ‘000), 2013-2018
  • Figure 4-6: China - Number of Births (Million), 2013-2018
  • Figure 4-7: China - Potential Market in Two Different Scenarios (US$), 2012
  • Figure 4-8: China - NIPT Market (Million US$), 2013-2018
  • Figure 4-9: China - NIPT Market (Volume ‘000), 2013-2018
  • Figure 4-10: Japan - Number of Births (‘000), 2013-2018
  • Figure 4-11: Japan - Number of Births by Mother's Risk of Down's syndrome (%), 2010
  • Figure 4-12: Japan - Potential Market in Two Different Scenarios (US$), 2013
  • Figure 4-13: Japan - NIPT Market (Million US$), 2013-2018
  • Figure 4-14: Japan - NIPT Market (Volume ‘00), 2013-2018
  • Figure 4-15: India - Number of Births (Million), 2013-2018

List of Tables:

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: MaterniT21 PLUS Test Validation Results
  • Table 3-3: Verifi Test Validation Results
  • Table 3-4: Panorma Test Validation Results
  • Table 3-5: Harmony Test Validation Results
  • Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
  • Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
  • Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
  • Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
  • Table 3-10: Risk of Down's syndrome with Rise in Maternal Age
  • Table 4-1: Australia - Number of Births by Age of Mother (2011)
  • Table 4-2: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
  • Table 4-3: China NIPT Market Landscape - Players; Cost per Test
  • Table 4-4: Japan - Number of Births by Age of Mother (2010)
  • Table 4-5: Japan NIPT Market Landscape - Player; Cost per Test
Back to Top